Bristol-Myers Squibb Co logo

CELG RT - Bristol-Myers Squibb Co Share Price

$0.399 -0.0  -4.7%

Last Trade - 9:10pm

Large Cap
Market Cap £102.94bn
Enterprise Value £122.02bn
Revenue £26.52bn
Position in Universe 71st / 6440
Unlock CELG RT Revenue
Relative Strength (%)
1m -10.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -43.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
15,879 16,560 19,427 20,776 22,561 26,145 41,972 45,692 +10.5%
-17.1 -22.3 +117.6 +27.1 +24.5 -37.4 +164.9 +17.9
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Bristol-Myers Squibb Co revenues increased 71% to $20.91B. Net loss totaled $860M vs. income of $3.14B. Revenues reflect Prioritized Brands-Eliquis segment increase of 21% to $4.8B, Prioritized Brands-Orencia segment increase of 3% to $1.46B, United States segment increase of 86% to $13.25B, Europe segment increase of 58% to $4.7B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CELG RT Revenue Unlock CELG RT Revenue

Net Income

CELG RT Net Income Unlock CELG RT Revenue

Normalised EPS

CELG RT Normalised EPS Unlock CELG RT Revenue

PE Ratio Range

CELG RT PE Ratio Range Unlock CELG RT Revenue

Dividend Yield Range

CELG RT Dividend Yield Range Unlock CELG RT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CELG RT EPS Forecasts Unlock CELG RT Revenue
Profile Summary

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated August 11, 1933
Public Since July 5, 1929
No. of Shareholders: 37,643
No. of Employees: 30,000
Sector Healthcare
Industry Pharmaceuticals
Exchange New York Stock Exchange (Dual Listing)
Shares in Issue 2,254,000,000
Free Float (0.0%)
Eligible for
CELG RT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CELG RT
Upcoming Events for CELG RT
Frequently Asked Questions for Bristol-Myers Squibb Co
What is the Bristol-Myers Squibb Co share price?

As of 9:10pm, shares in Bristol-Myers Squibb Co are trading at $0.399, giving the company a market capitalisation of £102.94bn. This share price information is delayed by 15 minutes.

How has the Bristol-Myers Squibb Co share price performed this year?

Shares in Bristol-Myers Squibb Co are currently trading at $0.399 and the price has moved by -7.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bristol-Myers Squibb Co price has moved by -18.94% over the past year.

What are the analyst and broker recommendations for Bristol-Myers Squibb Co?

There are no analysts currently covering Bristol-Myers Squibb Co.

When will Bristol-Myers Squibb Co next release its financial results?

Bristol-Myers Squibb Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Bristol-Myers Squibb Co dividend yield?

The Bristol-Myers Squibb Co dividend yield is 0.411k% based on the trailing twelve month period.

Does Bristol-Myers Squibb Co pay a dividend?

Last year, Bristol-Myers Squibb Co paid a total dividend of 1.72, and it currently has a trailing dividend yield of 0.411k%. Looking ahead, Bristol-Myers Squibb Co has not announced an ex-dividend date yet.

When does Bristol-Myers Squibb Co next pay dividends?

Bristol-Myers Squibb Co has yet to annouce their ex-dividend date. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 0.411k%.

How do I buy Bristol-Myers Squibb Co shares?

To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bristol-Myers Squibb Co?

Shares in Bristol-Myers Squibb Co are currently trading at $0.399, giving the company a market capitalisation of £102.94bn.

Where are Bristol-Myers Squibb Co shares listed? Where are Bristol-Myers Squibb Co shares listed?

Here are the trading details for Bristol-Myers Squibb Co:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: CELG RT
What kind of share is Bristol-Myers Squibb Co?

Based on an overall assessment of its quality, value and momentum, Bristol-Myers Squibb Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bristol-Myers Squibb Co share price forecast 2020?

Shares in Bristol-Myers Squibb Co are currently priced at $0.399. At that level they are trading at 17.5% discount to the analyst consensus target price of 0.00.

Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of 6.272 for the next financial year.

How can I tell whether the Bristol-Myers Squibb Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, the relative strength of its shares against the market has been -26.83%. At the current price of $0.399, shares in Bristol-Myers Squibb Co are trading at -11.91% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bristol-Myers Squibb Co PE Ratio?

The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 4.21. The shares are currently trading at $0.399.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bristol-Myers Squibb Co?

Bristol-Myers Squibb Co's management team is headed by:

Sandra Leung - EVP
Vicki Sato - LED
Giovanni Caforio - CHM
John Elicker - EVP
Ann Judge - CHO
Peter Arduini - IND
Robert Bertolini - IND
Matthew Emmens - IND
Christopher Boerner - EVP
Michael Bonney - IND
Kathryn Metcalfe - EVP
David Elkins - CFO
Nadim Ahmed - EVP
Samit Hirawat - EVP
Elizabeth Mily - EVP
Who are the major shareholders of Bristol-Myers Squibb Co?

Here are the top five shareholders of Bristol-Myers Squibb Co based on the size of their shareholding:

Redpoint Investment Management Pty Ltd. Investment Advisor
Percentage owned: % (21.1k shares)
ClearArc Capital, Inc. Investment Advisor
Percentage owned: % (20.0k shares)
California Public Employees' Retirement System Pension Fund
Percentage owned: % (17.9k shares)
Susquehanna International Group, LLP Investment Advisor
Percentage owned: % (26.8k shares)
Private Advisor Group LLC Investment Advisor
Percentage owned: % (15.0k shares)
Similar to CELG RT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.